Global Intravenous Immunoglobulins Market 2017-2021

  • ID: 4298775
  • Report
  • Region: Global
  • 70 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • ADMA Biologics
  • Bharat Serum and Vaccines
  • China Biologic Products
  • Grifols
  • LFB Group
  • Sanquin
  • MORE
About Intravenous Immunoglobulins

Immunoglobulins are glycoprotein molecules produced by plasma cells. They are a critical part of a body's immune response and they do so by specifically recognizing and binding to microbes and destroying them. These immunoglobulins are produced by a body naturally, but due to some genetic or infectious diseases, the natural production of immunoglobulin is inhibited, resulting in an immune-compromised condition.

The analysts forecast the global intravenous immunoglobulins market to grow at a CAGR of 7.62% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global intravenous immunoglobulins market for 2017-2021. To calculate the market size, the report considers sales from both generic and branded drugs.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Intravenous Immunoglobulins Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- CSL Behring
- Grifols
- Octapharma
- Shire

Other prominent vendors
- ADMA Biologics
- Bayer
- Bharat Serum and Vaccines
- Biotest AG
- China Biologic Products
- Hualan Biological Engineering
- Kedrion Biopharma
- LFB Group
- Sanquin

Market drivers
- Growing number of fractionating units
- For a full, detailed list, view the full report

Market challenges
- Complex and cost-intensive manufacturing
- For a full, detailed list, view the full report

Market trends
- Monetary support to plasma donors
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • ADMA Biologics
  • Bharat Serum and Vaccines
  • China Biologic Products
  • Grifols
  • LFB Group
  • Sanquin
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Market outline
PART 05: An overview of diseases treated using intravenous immunoglobulins

PART 06: Market landscape
  • Market overview
  • Five forces analysis
PART 07: Pipeline landscape

PART 08: Market segmentation by Therapy area
  • Global intravenous immunoglobulins market by neurology
  • Global intravenous immunoglobins market for hematology
  • Global intravenous immunoglobins market for immunology
  • Global intravenous immunoglobins market for others
PART 09: Geographical segmentation
  • Intravenous immunoglobulins market in Americas
  • Intravenous immunoglobulins market in EMEA
  • Intravenous immunoglobulins market in APAC
PART 10: Decision framework

PART 11: Drivers and challenges
  • Market drivers
  • Market challenges
PART 12: Market trends
  • Shift in manufacturing facilities to low-cost regions
  • Monetary support to plasma donors
PART 13: Vendor landscape
  • Competitive scenario
PART 14: Key vendor analysis
  • CSL Behring
  • Grifols
  • Octapharma
  • Shire
  • Other prominent vendors
PART 15: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Major diseases treated using intravenous immunoglobins therapy
Exhibit 02: Global intravenous immunoglobulins market snapshot
Exhibit 03: Global intravenous immunoglobins market 2016-2021 ($ millions)
Exhibit 04: Opportunity analysis in global intravenous immunoglobulins market
Exhibit 05: Five forces analysis
Exhibit 06: Pipeline analysis of vendors
Exhibit 07: Key clinical trials 2016
Exhibit 08: Global intravenous immunoglobulin market by therapy area 2016
Exhibit 09: Global intravenous immunoglobins market for neurology 2016-2021 ($ million)
Exhibit 10: Global intravenous immunoglobins market by hematology 2016-2021 ($ million)
Exhibit 11: Global intravenous immunoglobins market for immunology 2016-2021 ($ million)
Exhibit 12: Global intravenous immunoglobins market for others 2016-2021 ($ million)
Exhibit 13: Global intravenous immunoglobulin market by geography 2016 and 2021
Exhibit 14: Global intravenous immunoglobulin market by geography 2016-2021 ($ millions)
Exhibit 15: Market scenario in Americas
Exhibit 16: Intravenous immunoglobulins market in Americas 2016-2021 ($ millions)
Exhibit 17: North America: Percentage of global fractionation capacities 1999-2012
Exhibit 18: Market Scenario in EMEA
Exhibit 19: Intravenous immunoglobulins market in EMEA 2016-2021 ($ million)
Exhibit 20: Europe: percentage of global fractionation capacities 1999-2012
Exhibit 21: Market Scenario in APAC
Exhibit 22: Intravenous immunoglobulins market in APAC 2016-2021 ($ million)
Exhibit 23: APAC: Percentage of global fractionation capacities 1999-2012
Exhibit 24: Fractionation capacities of key vendors
Exhibit 25: Factors contributing to overall cost of immunoglobulin production
Exhibit 26: Various side-effects associated with immunoglobulin therapy
Exhibit 27: Regulatory requirements for TGA approval
Exhibit 28: Fractionating capacities globally 2007 and 2012
Exhibit 29: Competitive structure analysis of global intravenous immunoglobulins market 2016
Exhibit 30: Competitive factors in global intravenous immunoglobulins market
Exhibit 31: Market penetration of manufacturers of intravenous immunoglobulins worldwide 2016
Exhibit 32: Strategic success factors of companies in global intravenous immunoglobulins market
Exhibit 33: Key news in IVIG market
Exhibit 34: CSL Behring: Key Highlights
Exhibit 35: CSL Behring: Strength assessment
Exhibit 36: CSL Behring: Strategy assessment
Exhibit 37: CSL Behring: Opportunity assessment
Exhibit 38: Grifols: Key highlights
Exhibit 39: Grifols: Strength assessment
Exhibit 40: Grifols: Strategy assessment
Exhibit 41: Grifols: Opportunity assessment
Exhibit 42: Octapharma: Key highlights
Exhibit 43: Octapharma: Strength assessment
Exhibit 44: Octapharma: Strategy assessment
Exhibit 45: Octapharma: Opportunity assessment
Exhibit 46: Shire: Key highlights
Exhibit 47: Shire: Strength assessment
Exhibit 48: Shire: Strategy assessment
Exhibit 49: Shire: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • ADMA Biologics
  • Bharat Serum and Vaccines
  • China Biologic Products
  • Grifols
  • LFB Group
  • Sanquin
  • MORE
New Report Released: - Global Intravenous Immunoglobulins Market 2017-2021

The author of the report recognizes the following companies as the key players in the global intravenous immunoglobulins market: CSL Behring, Grifols, Octapharma, and Shire.

Other Prominent Vendors in the market are: ADMA Biologics, Bayer, Bharat Serum and Vaccines, Biotest AG, China Biologic Products, Hualan Biological Engineering, Kedrion Biopharma, LFB Group, and Sanquin.

Commenting on the report, an analyst from the research team said: “One trend in the market is monetary support to plasma donors. The intravenous immunoglobulin market is growing at steady rate, where the number of plasma donors affects the overall supply chain. Therefore, to maintain and meet the demands of plasma-derived therapeutics, a plasma donor receives monetary compensation.”

According to the report, one driver in the market is growing number of fractionating units. Fractionation is a crucial step in the manufacture of immunoglobulins. This step involves separation of immunoglobulins and other blood protein from plasma. The capacity of fractionating units is increasing. Data estimates suggest that during 2013-2016, the capacity increased by 39.5%. This increased capacity is primarily due to the installment of new fractionating units or expansion of existing fractionating units.

Further, the report states that one challenge in the market is complex and cost-intensive manufacturing. Immunoglobulin manufacturing involves complex, time and cost consuming stages. The process starts from collection of plasma from volunteers. It is followed by plasma fractionation coupled with virus and prion removals. This step is followed by in-vitro testing, which ensures the safety, efficacy and potency of manufactured immunoglobulin.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • CSL Behring
  • Grifols
  • Octapharma
  • Shire
  • ADMA Biologics
  • Bayer
  • Bharat Serum and Vaccines
  • Biotest AG
  • China Biologic Products
  • Hualan Biological Engineering
  • Kedrion Biopharma
  • LFB Group
  • Sanquin
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll